GLP-1 receptor agonists are associated with a significant reduction in (SBP) of -3.14 mmHg in patients with obesity.
Patients without diabetes experienced a greater reduction in SBP (-3.80 mmHg) compared to those with diabetes (-2.13 mmHg).
Among patients with diabetes, liraglutide at doses less than 2 mg resulted in a notable SBP reduction of -3.78 mmHg.
Efpeglenatide at doses of 6 mg or less showed the highest SBP reduction of -6.00 mmHg in patients without diabetes.
The change in SBP appears to be only slightly influenced by the specific drug-dose combination.
Reductions in SBP may be related to the amount of weight loss experienced by patients.
Simplified
The effect of (GLP-1RAs) on (SBP) in patients with obesity with or without diabetes remains unclear. The aim was to compare the effect of different drug-dose combinations of GLP-1RAs on SBP. The secondary aim was to assess whether changes in SBP with GLP-1RAs are associated with weight change. MEDLINE and Cochrane were searched until January 2022 for randomized control trials (RCTs) on patients with obesity, evaluating the impact of semaglutide, liraglutide, efpeglenatide, or exenatide on SBP. Separate analyses were done for trials with and without diabetes. Multivariate meta-regression assessed if SBP changes with GLP-1RA varied based on weight change or follow-up duration. Thirty-five RCTs were included. Follow-up duration ranged from 12 to 68 weeks for T2DM and 12-56 weeks for non-T2DM patients. GLP-1RAs significantly lowered SBP for all patients (MD = -3.14 [-3.60; -2.68]). Subgroup analysis showed a significantly greater difference in SBP reduction for patients without diabetes (-3.80 [-4.24; -3.37]) when compared with patients with diabetes (-2.13 [-3.27; -1.00]). Among patients with diabetes, liraglutide < 2 mg OD showed the greatest reduction in SBP (-3.78 [-6.27; -1.28]), while efpeglenatide ≤ 6 mg QW showed the greatest reduction in SBP (-6.00 [-9.89; -2.11]) in patients without diabetes. GLP-1RAs result in mild reductions in SBP in patients with obesity. The change in SBP varies only slightly by the drug-dose combination and appears to be related to the amount of weight loss.
Key numbers
-3.14 mmHg
Mean Reduction
Overall reduction in for all patients receiving GLP-1RAs.
-3.80 mmHg
Reduction in Patients Without Diabetes
Reduction in for patients without diabetes treated with GLP-1RAs.
-2.13 mmHg
Reduction in Patients With Diabetes
Reduction in for patients with diabetes treated with GLP-1RAs.
Full Text
We can’t show the full text here under this license.
